MODERNA COVID-19 VACCINATION SCHEDULE AND DOSING
FOR IMMUNOCOMPROMISED POPULATIONS

Moderna
Ages 6 months–5 years
dose/injection volume (Do NOT dilute before use)
Primary Dose: Blue Cap (magenta label)

Moderna
Ages 6 years–11 years
dose/injection volume (Do NOT dilute before use)
Primary Dose: Blue Cap (purple label)

Moderna
Ages 12 years–17 years
dose/injection volume (Do NOT dilute before use)
Primary Dose: Red Cap (blue label)

Moderna
Ages 18 years and older
dose/injection volume (Do NOT dilute before use)
Primary Dose: Red Cap (blue label)
Bivalent Booster: Dark Blue Cap (gray label)

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).
‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: CDC.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.